Clinical trials: Placebo Response
PBC
Obeticholic Acid Versus Placebo, in Combination with Ursodeoxycholic Acid in Patients with Primary Biliary Cirrhosis
This is a Phase III, randomized, double-blind, multicentre study assessing the efficacy and safety of obecholic acid and Ursodeoxycholic Acid(UDCA) compared with placebo and UDCA in treating of primary biliary cirrhosis (PBC) in…
- Trial name
- NCT06715319
- Testing
- OCA, UDCA
- Where
- China
- Volunteers
- 100 people
- Sponsor
- Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd.
Chest Pain, Gastroesophageal Reflux
Chest Pain Pilot Study
The purpose of this study is to compare the efficacy of Nexium® with placebo in relief of acid related pain or discomfort in the chest.
- Trial name
- NCT00251901
- Testing
- Esomeprazole
- Where
- 80 sites in Canada, Denmark and 4 more
- Volunteers
- 600 people
- Sponsor
- AstraZeneca
HIV Infections, HIV Wasting Syndrome
Growth Hormone in the Treatment of HIV-Associated Wasting
The purpose of this study is to compare physical function and lean body mass in patients getting different doses of somatropin compared to patients not getting the drug.
- Trial name
- NCT00489528
- Testing
- Somatropin; Recombinant human growth hormone (r hGH)
- Sponsor
- EMD Serono
Interstitial Cystitis
Phase II Study Efficacy and Safety of Two Dosing Regimens of MN-001 in Patients With Interstitial Cystitis
To evaluate the safety and efficacy of 8 weeks of treatment with MN-001 at 500 mg bid, 500 mg once daily vs. placebo in patients with Interstitial Cystitis.
- Trial name
- NCT00295854
- Testing
- MN-001 BID, MN-001
- Where
- 28 sites in United States
- Volunteers
- 296 people
- Sponsor
- MediciNova
Primary Fibromyalgia
Safety and Efficacy of Milnacipran in Pediatric Patients With Primary Fibromyalgia
The purpose of this study is to evaluate the safety, tolerability, efficacy, and pharmacokinetics of milnacipran in pediatric patients aged 13 to 17 years with primary fibromyalgia.
- Trial name
- MyFi (NCT01328002)
- Testing
- Milnacipran
- Where
- 47 sites in United States
- Volunteers
- 116 people
- Sponsor
- Forest Laboratories
Hypertension
A Study of the Effectiveness and Safety of Ramipril in the Treatment of Hypertension in Children and Adolescents
The primary purpose of this study is to evaluate the blood pressure lowering effects of ramipril, an FDA-approved drug for the treatment of hypertension in adults, in children and adolescents aged 6 to 16 years with hypertension.
- Trial name
- NCT00389519
- Testing
- ramipril
- Where
- 100 sites in United States, Argentina and 7 more
- Volunteers
- 422 people
- Sponsor
- Pfizer
Diverticulitis
Two Doses Mesalazine Granules Versus Placebo for the Prevention of Recurrence of Diverticulitis
The purpose of the study is to determine which dose of mesalazine granules compared to placebo is more effective in the prevention of recurrence of disease.
- Trial name
- NCT01038739
- Testing
- Mesalazine
- Where
- United States
- Volunteers
- 330 people
- Sponsor
- Dr. Falk Pharma GmbH
Plaque Psoriasis
A Study to Evaluate the Effects of Efalizumab on Immune Responses in Subjects With Moderate Plaque Psoriasis
This is a Phase I, randomized, placebo-controlled, single blind, parallel group, single-center study designed to evaluate immune responses during and after administration of 12 weekly SC doses of 1.0 mg/kg efalizumab in subjects…
- Trial name
- NCT00382512
- Testing
- Raptiva (efalizumab)
- Volunteers
- 60 people
- Sponsor
- Genentech, Inc.
Rhinitis, Allergic, Perennial, Allergic Rhinitis
A Randomised, Double Blind, Placebo Controlled, 4 Period, Incomplete Block, Crossover Study Assessing the Dose-response Curve of Fluticasone Propionate in an Antigen Challenge Chamber
This is a single-centre, randomised, double-blind, four-period, incomplete block, crossover study, with 8 days repeat dosing of intranasal Fluticasone Propionate (25, 50, 100, 200ug) and/or placebo in the Vienna Challenge Chamber…
- Trial name
- NCT00848965
- Testing
- Fluticasone propionate
- Where
- Austria
- Volunteers
- 59 people
- Sponsor
- GlaxoSmithKline
Healthy
A Study of Abemaciclib in Healthy Participants
The purposes of this study are to determine: The effect of single increasing doses of the study drug, abemaciclib, on healthy participants.
- Trial name
- NCT02677844
- Testing
- Abemaciclib, Loperamide
- Where
- 2 sites in United States
- Volunteers
- 35 people, healthy volunteers welcome
- Sponsor
- Eli Lilly and Company
Schizophrenia
Trial Evaluating Three Fixed Doses of Paliperidone Extended-Release (ER) Tablets and Olanzapine in the Treatment of Patients With Schizophrenia
The primary objective of the double-blind phase of this study is to evaluate the efficacy and safety of 3 fixed dosages of paliperidone ER (3, 9, and 15 mg/day) compared with placebo in adult patients with schizophrenia
- Trial name
- NCT00083668
- Testing
- Paliperidone ER
- Volunteers
- 619 people
- Sponsor
- Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Rheumatoid Arthritis
A Study to Evaluate Efficacy and Safety of ASP015K in Patients With Rheumatoid Arthritis (RA) Who Had an Inadequate Response to Methotrexate (MTX) Treatment
The objective of this study was to verify the efficacy of ASP015K versus placebo administrated in combination with methotrexate (MTX) over placebo in terms of efficacy in participants with rheumatoid arthritis (RA) who had an…
- Trial name
- NCT02305849
- Testing
- Peficitinib, Methotrexate
- Where
- 146 sites in Japan
- Volunteers
- 519 people
- Sponsor
- Astellas Pharma Inc
Influenza, Human
Effects of p38 MAPK Inhibitor POLB 001 on in Vivo LPS Challenge Responses
A single center trial to evaluate the effect of POLB 001 on inflammatory responses following an intradermal LPS challenge in healthy volunteers.
- Trial name
- NCT05765955
- Testing
- POLB 001
- Where
- Netherlands
- Volunteers
- 36 people, healthy volunteers welcome
- Sponsor
- Poolbeg Pharma plc
Hepatitis C, Chronic
Oral Antivirals (GS-5885, Tegobuvir, and/or GS-9451) With Peginterferon Alfa 2a and Ribavirin in Treatment Experienced Subjects With Chronic Genotype 1 Hepatitis C Virus Infection
This is a Phase 2b, Randomized, Double-Blind, Placebo-Controlled Trial Evaluating Response Guided Therapy using Combinations of Oral Antivirals (GS-5885, tegobuvir, and/or GS-9451) with Peginterferon Alfa 2a and Ribavirin in…
- Trial name
- NCT01371578
- Testing
- GS-5885 tablet, GS-9451 tablet, peginterferon alfa-2a
- Where
- 55 sites in United States, Puerto Rico
- Volunteers
- 163 people
- Sponsor
- Gilead Sciences
Depressive Disorder, Treatment-Resistant
Efficacy, Safety, and Tolerability Study of AVP-786 as an Adjunctive Therapy in Patients With Major Depressive Disorder With an Inadequate Response to Antidepressant Treatment
The objectives of this 10-week study are to evaluate the efficacy, safety, and tolerability of AVP 786 as an adjunctive therapy compared with placebo in patients with major depressive disorder (MDD) who have shown an inadequate…
- Trial name
- NCT02153502
- Testing
- AVP-786 (d6-dextromethorphan hydrobromide and quinidine sulfate combination)
- Where
- 32 sites in United States
- Volunteers
- 206 people
- Sponsor
- Otsuka Pharmaceutical Development & Commercialization, Inc.
Rheumatoid Arthritis
A Study to Evaluate Safety and Efficacy of ASP015K in Patients With Rheumatoid Arthritis (RA) Who Had an Inadequate Response to DMARDs
The objective of this study was to verify the superiority of ASP015K alone or in combination with disease-modifying antirheumatic drugs (DMARDs) over placebo in terms of efficacy in participants with rheumatoid arthritis (RA) who…
- Trial name
- NCT02308163
- Testing
- Peficitinib, Etanercept
- Where
- 153 sites in Japan, South Korea and 1 more
- Volunteers
- 509 people
- Sponsor
- Astellas Pharma Inc
Asthma
A Study to Evaluate the Effect of GW870086X on Allergen Challenge in Mild Asthmatics
The study will measure the early and late asthamtic response using an allergen challenge. This study will evaluate the safety and patients tolerance to repeat inhaled doses of GW870086X using a number of clinical and biological…
- Trial name
- NCT00857857
- Testing
- GW870086X, FP
- Where
- 4 sites in Germany
- Volunteers
- 24 people
- Sponsor
- GlaxoSmithKline
Ebola Virus
Placebo Controlled, Dose Response, Safety and Immunogenicity Study of Vesicular Stomatitis Virus (VSV) Ebola Vaccine in Healthy Adults (V920-004)
Ebola virus has infected and killed people, mostly in Africa. In 2014, the Ebola virus has affected several thousand people. There is no approved effective way to treat or prevent Ebola.
- Trial name
- NCT02314923
- Testing
- V920 Vaccine
- Volunteers
- 513 people, healthy volunteers welcome
- Sponsor
- Merck Sharp & Dohme LLC
Diabetes Mellitus, Type 2
Phase 1/2a, Randomized, Double-Blind, Placebo-Controlled, Study to Assess Safety, Tolerability, PK and PD Response of PB1023 Injection Following Single and Multiple SQ Doses in Adults With Type 2 Diabetes Mellitus
Primary objective: To evaluate the safety and tolerability of single and multiple ascending doses of PB1023 administered as a subcutaneous (SC) injection in adult subjects with T2DM. Secondary objectives: 1.
- Trial name
- NCT01236404
- Where
- 3 sites in United States
- Volunteers
- 80 people
- Sponsor
- PhaseBio Pharmaceuticals Inc.
Schizophrenia
A 52-week, Open-label Extension Study Following a 6-week, Double-blind, Placebo- and Active- Controlled Study (R076477-SCH-303) to Evaluate the Safety and Tolerability of Paliperidone ER in Subjects With Schizophrenia
The purpose of the study was an Open Label Extension to a completed study that evaluated the efficacy and safety of 3 fixed dosages of Extended Release OROS® Paliperidone
- Trial name
- NCT00650793
- Testing
- Extended Release OROS® Paliperidone
- Volunteers
- 473 people
- Sponsor
- Johnson & Johnson Pharmaceutical Research & Development, L.L.C.